Evidence is accumulating about the role of individual AP-1 components in cell proliferation and transformation. Notably, Ras-mediated transformation is characterized by the upregulation of particular AP-1 members, such as c-Jun and Fra-1. The p14/p19 ARF tumor suppressor gene is a key link between oncogenic Ras signaling and the p53 pathway. We explored the involvement of AP-1 dimers in the transcriptional regulation of the p14/p19
Introduction
The CDKN2A locus encodes two tumor suppressors, p16 INK4A and p14 ARF (p19 ARF in mouse), that play key roles in the cellular response to oncogenic stress. This locus is commonly deleted, mutated or silenced by DNA methylation in human tumors (Sherr, 2001) . The genomic organization of the CDKN2A locus is unusual, as the two overlapping genes, p16
INK4A and p14/p19 ARF , are regulated by distinct promoters and encode two unrelated proteins (Quelle et al., 1995; Sherr, 2001) . p16 INK4A and p14/p19 ARF play important roles in regulating the cell cycle and the integration of stress pathways and cellular outcomes. The p16
INK4A protein inhibits cell-cycle progression by repressing the activity of CDK4/6 cyclin complexes and preventing the phosphorylation of pRb, whereas the p14/p19 ARF protein regulates the p53 pathway (Serrano et al., 1996; Kamijo et al., 1997) .
The p14/p19 ARF tumor suppressor induces cell-cycle arrest or apoptosis, in part, via stabilization of the p53 tumor suppressor protein. This may be achieved by sequestering MDM2 in the nucleolus, thereby inhibiting its E3 ubiquitin ligase activity (Kamijo et al., 1998; Pomerantz et al., 1998; Stott et al., 1998; Tao and Levine, 1999; Weber et al., 1999) . Recent studies, however, have revealed that ARF can stabilize p53 without MDM2 relocalization (Llanos et al., 2001; Korgaonkar et al., 2002) , and that ARF proteins have additional p53-independent functions. For example, ARF can induce cell-cycle arrest in mouse embryo fibroblasts (MEFs) lacking p21 CIP1 or p53 (Pantoja and Serrano, 1999; Weber et al., 2000; Modestou et al., 2001) . The p53-independent effects of ARF may be mediated by the induction of additional downstream effectors . ARF can repress ribosomal RNA processing in the nucleolus independently of p53 (Itahana et al., 2003; Sugimoto et al., 2003) . The recent demonstration that ARF also inhibits NF-kB transactivation, via a mechanism that is p53-independent, suggests additional roles for this protein in controlling the response to oncogenic activation (Rocha et al., 2003) .
The p14/p19 ARF gene is induced by many oncogenes, including E1A, c-Myc, E2F, v-Abl, b-catenin and Ras (Sherr, 2001) . Early studies linked the E2F transcription factor to the induction of the ARF gene by oncogenic Ras signaling . However, subsequent attempts to demonstrate the importance of E2F suggest that the regulation of this promoter is complex and involves the convergence of multiple transcription factors. It was demonstrated that overexpression of E2F leads to the activation of the ARF gene independently of the E2F-binding sites in its promoter (Parisi et al., 2002; Berkovich et al., 2003) . Intriguingly, while deregulated E2F activates the p14 ARF gene, E2F-pRb complexes negatively regulate this promoter Rowland et al., 2002) . The ARF promoter is also regulated by Sp-1 and DMP1 transcription factors (Inoue et al., 1999; Parisi et al., 2002; Berkovich et al., 2003) . Other proteins repress transcription of the ARF gene, including Twist, p53, T-box factors and Bmi-1 (Robertson and Jones, 1998; Jacobs et al., 1999; Maestro et al., 1999) .
Both p16 INK4A and p19 ARF proteins accumulate in primary MEFs in culture and their overexpression leads to cellular senescence . Disabling ARF function alone allows cells to bypass senescence and is necessary for the immortalization of MEFs, mouse pre-B cells, keratinocytes and astrocytes, whereas loss of p16 INK4A in human fibroblasts or in MEFs does not bypass senescence (Krimpenfort et al., 2001; Sharpless et al., 2001) . Human cells seem to require disruption of both INK4A-pRb and ARF-p53 pathways to bypass replicative senescence (Drayton et al., 2003; Lowe and Sherr, 2003) . This suggests that p19 ARF plays a more dominant role in mouse cells, compared to p16
INK4A in human cells, in regulating senescence and inhibiting transformation (Krimpenfort et al., 2001; Sharpless et al., 2001; Brookes et al., 2002) .
The AP-1 transcription factor plays critical roles in regulating cell proliferation, transformation and Ras signaling. AP-1 is composed of proteins belonging to the basic leucine zipper family. AP-1 is a dimer containing members of the Jun family (c-Jun, JunB and JunD) with dimerizing partners belonging to the Fos (c-Fos, FosB, Fra-1 and Fra-2) or ATF families (Mechta-Grigoriou et al., 2001; van Dam and Castellazzi, 2001 ). The AP-1 complex binds to a TPA-responsive element (TRE) 5 0 -TGA(C/G)TCA that is present in many promoters. Experiments involving the inactivation or overexpression of different jun and fos/fra genes have provided insights into how AP-1 modulates cell proliferation . AP-1 can elicit different genetic programs, depending on the cellular context and the dimer composition, leading to distinct cellular fates. A model has emerged in which some AP-1 members activate oncogenic or mitogenic target genes, while others activate antagonistic or inhibitory pathways. For example, JunB specifically activates the p16 INK4A tumor suppressor gene, leading to cell-cycle arrest (Passegue and Wagner, 2000) . Conversely, c-Jun inhibits the transactivating function of p53, and the subsequent upregulation of the p21 Cip1 gene, in response to UV (Shaulian et al., 2000) . Transcriptional activation of the cyclin D1 gene is dependent on the ratio of c-Jun : JunB, as well as c-Jun : JunD, levels (Bakiri et al., 2000) . Antagonism between c-Jun and JunB dimers also regulates fibroblast proliferation and differentiation in the skin (Szabowski et al., 2000) . We recently observed that p19 ARF expression is increased in MEFs lacking JunD, implying an additional mechanistic link between AP-1 and cell-cycle genes (Weitzman et al., 2000) .
AP-1 plays a major role in Ras-induced cellular transformation in immortalized rodent and chicken fibroblasts (Schutte et al., 1989; Johnson et al., 1996) . c-Jun and Fra-1 proteins in particular were identified as major effectors of Ras-mediated transformation in immortalized cells (Mechta et al., 1997; Vallone et al., 1997; Behrens et al., 2000) . Moreover, c-Jun cooperates with Ras, whereas JunD can partially antagonize Ras transformation (Pfarr et al., 1994) . Thus, it appears that specific AP-1 heterodimers act downstream of oncogenic Ras to initiate genetic programs, which, depending on the cellular context, may lead to cell proliferation, apoptosis, senescence or transformation. We recently developed a set of 'tethered heterodimers' that offer an elegant tool to address the question of specific biological functions and specific target genes of AP-1 dimers (Bakiri et al., 2002) .
In this study, we examined whether transcription of the human p14 ARF and mouse p19 ARF genes is regulated by the AP-1 transcription factor. We demonstrate that AP-1 dimers containing Fra-1 regulate both genes and influence the cellular outcome. We also show that AP-1 heterodimers cooperate with Ras to activate the ARF promoters. These results suggest that selective AP-1 heterodimers contribute to the regulation of the INK4A-ARF locus and to the control of the cell cycle.
Results
Selective AP-1 heterodimers regulate the human p14 ARF promoter To examine the role of AP-1 in regulating the human p14 ARF promoter, we employed a set of AP-1 'tethered heterodimers' that consist of Jun and Fos (or Fra-1) monomers fused via a synthetic peptide linker (Bakiri et al., 2002) . These tethered dimers have been shown to bind to DNA and activate transcription efficiently and are ideally suited for investigating the action of specific AP-1 heterodimers. We co-transfected a set of plasmids encoding tethered heterodimers together with a reporter construct containing over 5 kb of the p14 ARF promoter (p14 ARF -CAT) into human C33 cervical carcinoma cells (Robertson and Jones, 1998) . The p14 ARF promoter was strongly activated by the c-JunBFra-1 heterodimer, and to a lesser extent by JunDBFra-1, whereas Fra-2-containing dimers had little or no effect (Figure 1a ). The differences in Fra-1-containing dimer specificity were not observed when the AP-1 heterodimers were tested on a control reporter vector containing the mmp1 promoter (Figure 1b) . Furthermore, the expression levels of the different transfected heterodimers were equivalent in these cells (Figure 1c ), demonstrating that protein stability could not account for the differences in transactivation. We found that the c-JunBFra-1 heterodimer activated the p14 ARF promoter in a dose-responsive manner (Figure 1d ), whereas other heterodimers containing Fra-2 partners failed to induce the p14 ARF promoter even at higher concentrations (unpublished data). Furthermore, the strong activation by the c-JunBFra-1 tethered heterodimer could be reproduced using monomer proteins; transfection of individual plasmids encoding c-Jun and Fra-1 activated the p14 ARF promoter significantly more than c-Jun plus c-Fos or empty vector (Figure 1e ). These results demonstrate that the human p14 regulated by AP-1 heterodimers, and that dimers containing Fra-1 are the most effective transactivators of this promoter in human carcinoma cells. We therefore focused on the c-JunBFra-1 heterodimer in our study.
We next examined whether c-JunBFra-1 AP-1 heterodimers bind to TRE-like sequences present in the p14 ARF promoter. A previous study noted three putative distal TRE sites (located in positions À4977, À4829 and À3394 bp) in the p14 ARF promoter (Robertson and Jones, 1998). Using nuclear extracts from C33 cells transfected with c-JunBFra-1 heterodimers, we showed that AP-1 dimers can bind to these TRE-like elements from the distal region of the p14 ARF promoter, as well as they bind to a canonical TRE probe ( Figure 2a) . We examined the ability of c-JunBFra-1 to activate a set of deletion constructs of the p14 ARF promoter containing different numbers of TRE sites ( Figure 2b ) (Robertson and Jones, 1998) . Deletion of promoter regions containing all three TRE-like sites led to a marked decrease (over 60%) in AP-1 induction of the p14 ARF promoter (Figure 2b ). This deletion had no ARF promoter by Fra-1-containing dimers. (a) c-JunBFra-1 dimers bind to TRE sites in the distal p14 ARF promoter: EMSA experiments were performed using probes derived from a canonical TRE or from the p14 ARF promoter. Nuclear extracts were prepared from C33A cells that were untransfected (lane 1), mock transfected (lane 2), transfected with c-JunBFra-1 (lanes 3 and 5) or from serum-stimulated NIH3T3 fibroblasts (lanes 4 and 6). Extracts were incubated with the 32 Pradiolabeled probes (see Materials and methods). In lanes 5 and 6, the same extracts were first preincubated with an excess of cold competitor. effect on basal transcription levels. The residual AP-1 activation of the shorter promoter constructs suggests that there may be additional elements that do not resemble the classical TRE consensus sequence. This residual activation would complicate the interpretation of TRE mutation studies, as has been seen with mutation of individual E2F-binding sites in this promoter. It is clear, however, that AP-1 dimers can bind to TRE-like sequences in the distal promoter, and that these contribute to the induction of the human p14 ARF promoter by AP-1.
To demonstrate the importance of Fra-1-containing dimers in regulating the endogenous p14 ARF gene, we performed knockdown experiments using siRNA specific for the human Fra1 mRNA. Treatment with Fra-1 siRNA led to a marked reduction in Fra-1 protein levels and a concomitant drastic inhibition of p14 ARF expression (Figure 2c ), whereas control siRNA for the unrelated HP1-a protein did not affect p14 ARF levels. The ARF protein levels were greatly diminished despite the presence of residual Fra-1 expression, suggesting that there may be a minimum threshold of Fra-1-containing dimers required to maintain p14 ARF expression. These results suggest that the expression of Fra-1-containing AP-1 heterodimers is sufficient and necessary to drive the expression of the human p14 ARF gene.
AP-1 dimers regulate the mouse p19 ARF gene
We next examined whether Fra-1 heterodimers are also involved in the regulation of the murine p19 ARF gene. To allow direct comparison with the results described above, we first tested the effect of the Fra-1 heterodimers on the regulation of a 2.6 kb genomic DNA fragment of the p19 ARF promoter in C33 cells. We found that the p19 ARF promoter was activated by all Fra-1 heterodimers in these cells (Figure 3a) . The c-JunBFra-1 heterodimer was the most effective transactivator (sixfold activation), but the other Fra-1 heterodimers also exhibited several-fold transactivation (Figure 3a) , which was equivalent to that observed with E2F1, a wellcharacterized activator of this promoter ( Figure 3a) . As with the human promoter, JunDBFra-1 was a less potent activator than c-Jun-containing dimers. AP-1 dimers containing Fra-2 or c-Fos partners were even less effective transactivators than the weakest Fra-1-containing dimer JunDBFra-1 (data not shown). In control experiments, we found that the c-Jun-and JunDcontaining tethered dimers showed few differences in activation of the mmp1-Luc promoter construct (Figure 3b) . Thus, Fra-1-containing dimers are also capable of activating the murine p19 ARF promoter. To test whether the c-JunBFra-1 dimer also activates the murine p19 ARF promoter in mouse cells, we performed transfections in F9 teratocarcinoma cells that contain low levels of endogenous AP-1. We tested the c-JunBFra-1 dimer as it is the strongest transactivator of the human and mouse ARF promoters. The c-JunBFra-1 AP-1 heterodimers were also able to induce the murine ARF promoter in murine cells (Figure 3c) . In control experiments, the c-JunBFra-1 also activated the mmp1 promoter to similar levels in mouse cells.
Next, we investigated whether AP-1 heterodimers regulate the endogenous p19 ARF gene. Due to the availability of genetically modified murine fibroblasts, we chose this as our cellular model. We examined the consequences of altering c-Jun expression by comparing early passage primary MEFs derived from c-Jun knockout (c-JunÀ/À) or wild-type embryos. The levels of p19 ARF mRNA and protein increased in primary wildtype MEFs upon repeated passage in culture (Figure 4a and b). In MEFs lacking c-Jun, we observed a marked decrease in the accumulation of p19 ARF protein in early passage cells (Figure 4b ). This was accompanied by a decrease in p19 ARF mRNA levels measured by quantitative RT-PCR (Figure 4a ). The decrease in ARF expression in the absence of c-Jun confirms that c-Juncontaining dimers are regulators of the endogenous p19 ARF gene. We examined the cellular phenotypes associated with overexpression of the AP-1 heterodimers in mouse cells. We infected cells with retroviruses expressing either the tethered c-JunBFra-1 AP-1 heterodimer or oncogenic Ras (H-RasV12). The retroviral vectors express a puromycin resistance gene that allows selection of transduced cells. The expression of c-JunBFra-1 AP-1 dimers in primary MEFs resulted in wide-scale apoptosis hindering experimental analysis. We turned to p53-null MEFs, as in addition to its role in regulating p53 stability, ARF has been shown to induce cell-cycle arrest in a p53-independent manner (Weber et al., 2000) . We infected p53-null (p53À/À) MEFs with retroviruses encoding c-JunBFra-1 tethered heterodimers and observed an induction of the endogenous p19 ARF protein (Figure 4c ). After selection, there was a marked growth inhibition (40% increase in the G1 phase population) in (Figure 4d) . Thus, the upregulation of ARF expression by AP-1 dimers in murine fibroblasts correlated with cell-cycle inhibition. We failed to see growth arrest when AP-1 dimers were expressed in immortalized NIH3T3 cells that lack the p19ARF locus (unpublished data). This supports, although does not unequivocally prove, our conclusion that the induction of p19
ARF is the cause of AP-1-induced growth arrest. Future experiments in ARF/INK knockout cells will establish the relative contribution of these two pathways to AP-1-induced arrest.
AP-1 heterodimers cooperate with oncogenic Ras to activate the ARF promoter
The mechanism(s) by which oncogenic Ras induces the p14/p19 ARF tumor suppressor gene is still enigmatic. It was proposed that oncogenic Ras induces the mouse p19 ARF gene via the Raf pathway (Ries et al., 2000) . Berkovich et al. (2003) demonstrated that activated Ras cooperates with E2F in the transcriptional activation of the p14 ARF promoter, but other studies reported that Ras-induced p19 ARF expression is E2F-independent (Palmero et al., 2002) . Thus, the nuclear effectors of Ras in this context are still unclear. Since AP-1 is a downstream effector of Ras signaling pathways, we investigated potential functional cooperation between AP-1 and Ras in the regulation of the ARF genes. In our system, we found that coexpression of c-JunBFra-1 with Ras led to elevated p14 ARF promoter activation (Figure 5a ). We did not see a significant increase in the transcriptional activity of the p14 ARF promoter by c-JunBc-Fos or oncogenic Ras, alone or together (data not shown). The cooperative effects of Ras and AP-1 dimers were not observed on the mmp1 promoter (Figure 5b ). The expression of Ras with AP-1 dimers also resulted in increased p19 ARF promoter activity (Figure 5c-d) . We found that oncogenic Ras cooperated with c-JunBFra-1 in human C33 (Figure 5c ) cells and in NIH3T3 mouse cells (Figure 5d ). Independently of the extent of activation by oncogenic Ras alone, co-expression with AP-1 increased the transcriptional effect. Thus, c-JunBFra-1 AP-1 dimers appear to synergize with Ras to induce both mouse and human ARF promoters.
Ras is known to activate MAPK and JNK pathways leading to c-Jun phosphorylation. We examined the levels of c-Jun phosphorylation using phospho-Junspecific antibodies. We did not detect changes in the levels of phosphorylation of the Jun-containing dimers upon Ras transfection and JNK activation appears not to account for the synergy with Ras in our experimental system (unpublished data). Ras activation has many effector arms (including PI3-kinase and Raf) and it is possible that several of these act in parallel with AP-1 to drive ARF expression. To test this hypothesis, we examined the effect of ERK inhibition on the induction of the p19 ARF promoter. Fra-1-containing dimers were shown to be phosphorylated by the ERK kinase pathway (Young et al., 2002) . The inhibition of ERK using the U0126 drug significantly reduced induction of the p19 ARF promoter by the c-JunBFra-1 dimer, suggesting that ERK activity is essential for AP-1 regulation of the ARF gene (Figure 5e ). However, U0126 was less effective in blocking the synergic activation of the ARF promoter by c-JunBFra-1 with Ras ( Figure 5e ). These experiments were performed in cells grown in medium with serum where the basal activities of ERK and JNK pathways are relatively high. However, the mechanism by which Ras enhances AP-1 induction of the ARF promoter appears to be partially independent of the activation of JNK or ERK pathways, and likely proceeds via a parallel pathway.
Discussion
Here, we show for the first time that AP-1 is a direct transcriptional regulator of the human and mouse p14/ p19 ARF tumor suppressor gene. We show that this regulation is influenced by the heterodimer composition, and that c-JunBFra-1 AP-1 dimers cooperate with Ras to regulate the ARF promoters.
Early studies on AP-1 function focused mainly on its role in cell proliferation and transformation (Angel and Karin, 1991; Ameyar et al., 2003) . The last few years, however, have seen a shift in our understanding of the role of AP-1 in cell-fate decisions. Two important concepts have emerged: first, that AP-1 can regulate the expression of cell-cycle inhibitors, such as p16
INK4A
and p53, as well as genes associated with cell-cycle progression, such as cyclinD1; second, there is mounting evidence to suggest that distinct AP-1 heterodimers regulate different transcriptional programs leading to different cellular outcomes (Jochum et al., 2001) . The generation of genetically modified mice, and cell lines derived from them, has provided tools to examine these issues. In this study, we used genetically modified cells and a set of tethered dimers to investigate AP-1 function (Bakiri et al., 2002) .
We used tethered heterodimers to identify both the human and mouse ARF genes as transcriptional targets of AP-1. These results add p14 ARF and p19 ARF to the growing list of cell-cycle regulatory proteins that are controlled by AP-1. We show that c-JunBFra-1 AP-1 heterodimers can bind to TRE-like sequences in the human ARF promoter, can activate both human and mouse promoters in transfection studies and can regulate the expression levels of the endogenous p19 ARF gene. We propose that the cellular outcome associated with AP-1 activation will depend on the balance of specific AP-1 components and the combination of cellcycle regulatory genes in the AP-1-induced genetic program. The ARF gene acts as a sensor to oncogenic signals from a wide range of cellular pathways (Lowe and Sherr, 2003) . ARF is remarkably sensitive to transcriptional regulation, compared to many other tumor suppressors that are regulated mainly at the posttranscriptional level. This response to oncogenic stress illustrates why deletion of INK4A-ARF locus contributes to tumorigenesis. The role of AP-1 in regulating ARF expression is important for unraveling the tumorigenic process.
Oncogenic mutations in Ras are found in about 30% of human tumors (Bos et al., 1989) , and Ras activation leads to a wide range of effects, including proliferative signaling, cellular transformation and senescence. It appears that AP-1 heterodimers are important players in the effectors arms of the Ras activation pathway. Some of the cellular effects of Ras activation are associated with the regulation of the INK4a/ARF locus. This locus is particularly fascinating, as it regulates both the p53 and pRb pathways (Serrano, 2000) . Here, we show that one arm of this pathway links Ras and AP-1 to the induction of the ARF gene. The other gene in this locus, p16
, is regulated by JunB-containing dimers The inhibitor was added twice over a 24-h period. Cells were analysed for the induction of the ARF promoter and ERK levels were measured using specific antibodies against the phosphorylated activated form or the non-activated form of the kinase AP-1 regulates ARF expression M Ameyar-Zazoua et al (Passegue and Wagner, 2000) . Thus, specific AP-1 activity provides a link between Ras and p53, as well as Ras and pRb pathways.
We found that c-JunBFra-1 is a superior transactivator of the human p14 ARF promoter, despite the fact that other AP-1 heterodimers are also able to bind to the TRE sites upstream of the gene (unpublished data). Control experiments showed that this selectivity could not be explained by differential expression of the tethered dimers or their general transactivation activity (as they activated the mmp1 promoter to roughly similar extents). Other studies have identified promoters that are differentially regulated by c-Jun/ATF compared to c-Jun/Fos dimers (van Dam and Castellazzi, 2001 ). However, these differences are often due to differences in the DNA motifs bound by these different complexes (CRE vs TRE). The selective nature of the Fra-1-containing heterodimers on the ARF promoter is probably influenced by the surrounding promoter context and cooperation with other transcriptional regulators. Little is known about how different AP-1 heterodimers interact with other transcription factors and components of enhanceosome structures. It will be interesting to explore the role of additional proteins in determining the marked differences that we observed on the p14 ARF promoter. A large number of nuclear factors have been implicated in the complex regulation of the ARF genes (see Introduction) and it is possible that the cooperative regulation of the ARF gene by Ras and AP-1 involves physical or functional interactions with coactivators or with other transcription factors such E2F and Sp-1. Preliminary experiments, however, failed to establish a clear link between AP-1 and E2F in the regulation of the ARF genes; the two factors appear not to interact physically, nor to cooperate in the regulation of the ARF promoter (unpublished data).
A number of possible mechanisms might contribute to the functional cooperation between Ras and AP-1. These may involve the recruitment of coactivators, stabilization of enhanceosome formation, etc. Ras is known to activate MAPK and JNK pathways leading to c-Jun phosphorylation. However, we failed to observe an effect of Ras on the phosphorylation of c-JunBFra-1 heterodimers in our experimental system (unpublished data) and ERK inhibition did not completely block the cooperation with Ras (Figure 5e ). Ras activation has many effector arms (including PI3-kinase and Raf) and it is possible that several of these act in parallel with AP-1 to drive ARF expression. It is worth noting that oncogenic Ras, which can induce ARF expression in primary mouse fibroblasts, is specifically associated with the induction of the c-Jun and Fra-1 proteins in transformed NIH3T3 cells (Mechta et al., 1997) . For this reason, we focused our analysis on the c-JunBFra-1 tethered heterodimers. We have shown that the c-JunBFra-1 heterodimers are the most effective activators of both the ARF promoters. The human p14 ARF promoter appears to be regulated primarily by Fra-1-containing dimers and not by those containing Fra-2 or c-Fos (Figure 1 and data not shown) . Preliminary experiments, however, suggested that c-Fos-containing dimers can regulate the p19 ARF promoter. This raises the possibility that, while both promoters are regulated by AP-1, the mechanisms may vary between the two species. Furthermore, we found that oncogenic Ras cooperates with c-JunBc-Fos dimers on the mouse promoter but not on the human promoter (not shown). These differences are probably due to differences in promoter structure, sequences and interactions with cooperating factors. Bioinformatics analysis revealed that there is considerable homology between these promoters. The ARF promoters may be a good model for future studies to define dimer-and species-specific mechanisms for AP-1 gene regulation. Our siRNA experiments demonstrated that Fra-1 expression is necessary for ARF expression in human cells. It is worth noting that the siRNA experiments (Figure 2c) show that ARF expression is significantly reduced despite residual expression of Fra-1 protein. This suggests that there is a threshold of Fra-1 expression required to maintain ARF expression. Indeed, transfection experiments also show that the ARF promoter is very sensitive to the doses of c-JunBFra-1 heterodimers (Figure 1 ). We show that Fra-1 dimers containing JunB and JunD are significantly less effective in activating the human ARF promoter, thus it is likely that a threshold of Fra-1 expression must be achieved in order to form c-JunBFra-1 dimers and activate the ARF promoter. Furthermore, our analysis of cells from knockout mice confirmed that the endogenous ARF gene is regulated by AP-1 components. We found that p19 ARF levels are decreased in c-JunÀ/À MEFs, supporting the role of c-Jun as a positive regulator of ARF expression. In contrast, MEFs lacking JunD have elevated levels of p19 ARF expression, consistent with their senescence-like phenotype (Weitzman et al., 2000) . We found that JunD-containing dimers can regulate the ARF gene, but less efficiently than c-Jun heterodimers (Figures 1a and  3a) . We suggest that in the absence of JunD more potent c-Jun heterodimers can occupy the TRE sites in the ARF promoter driving higher expression. The balance between different AP-1 components appears to be critical for Ras-induced transformation (Pfarr et al., 1994) and we previously proposed that JunD acts as a buffer against AP-1 activity by its reduced transactivation potential (Bakiri et al., 2000; Weitzman et al., 2000) . A similar scenario accounts for the antagonistic regulation of the cyclinD1 gene by c-Jun and JunD heterodimers. We also observed modest, but reproducible, increases in p19 ARF mRNA levels (1.65-fold) in the lungs of mice overexpressing an Fra1 transgene and found a pronounced induction of p19 ARF mRNA in tissues derived from older Fra-1 transgenic mice harboring lung pathologies (data not shown). Taken together, these results provide genetic support for a regulation of endogenous p19 ARF expression by specific AP-1 dimers in both in vivo and in vitro contexts. It was recently shown that c-Fos, considered to be a potent proto-oncogene, is also capable of acting as a tumor suppressor gene (Fleischmann et al., 2003) . The formation of rhabdomyosarcomas in mice lacking both c-Fos and p53 emphasizes that the outcome of Ras and AP-1 AP-1 regulates ARF expression M Ameyar-Zazoua et al activation depends on the cellular context and the status of downstream cell-cycle regulators In conclusion, we have used specified AP-1 heterodimers to show that AP-1 contributes to the regulation of the human and mouse ARF genes. The c-JunBFra-1 heterodimer is the most potent activator of the ARF promoter. Unraveling the complex network of interactions linking distinct AP-1 dimers and components of the cell-cycle machinery is important for our understanding of the relative contribution of these players to tumor progression.
Materials and methods

Cell culture, transfections and reporter assays
Primary MEFs were explanted from E12.5 embryos and grown as described previously (Weitzman et al., 2000) . C33A cells, F9, NIH3T3 and MEF cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with fetal calf serum (7-10%, respectively), 500 IU/ml penicillin and 125 mg/ml streptomycin (Gibco-BRL). Transfection was performed by the calcium phosphate method for C33A cells and by using Lipofectamine 2000 for F9 and NIH3T3 cells, according to the manufacturer's instructions. C33A cells were co-transfected with p14 ARF -CAT promoter constructs (a gift from P Jones) and one of the following cDNA: the various Jun/Fos expression pCG-based vectors (Bakiri et al., 2002) , pcDNA3-H-RasV12 (provided by D Ginsberg). The amount of plasmid was kept constant by the addition of parental expression vector. CAT assays were performed as described previously (Thierry et al., 1987) . Quantification of the acetylated [
14 C]chloramphenicol was determined with a PhosphoImager (Molecular Dynamics). All results are presented as mean7s.d. of triplicate. For luciferase assay, cells were cotransfected with a Renilla luciferase expression vector and plasmids encoding Firefly luciferase under control of either the mouse ARF promoter (2.6 kb genomic DNA fragment, gift from C Sherr) or the collagenase promoter (mmp1-Luc).
For siRNA transfections, HeLa cells were seeded at 50% confluence in six-well plates in ATB-free medium 24 h prior to transfection. Cells were transfected with 50-100 pmol of siRNA duplex using the Lipofectamine 2000 reagent, according to the manufacturer's instructions. Rational design of siRNAs was performed using the Sfold software (http:// sfold.wadsworth.org).
siRNA-hHP1a 5 0 -CACAAAUUGUGAUAGCAUUdTdT and siRNA-FRA1 5 0 -CCACUUUACCCACCUAGAAdTdT.
Nuclear extracts and electrophoretic mobility shift assays
Nuclear extracts were prepared according to established procedures (Dignam et al., 1983) . Briefly, 3 mg of nuclear extracts were preincubated in solution (HEPES 10 mM, pH 7.9, glycerol 25%, MgCl 2 1.5 mM, EDTA 0.25 mM, pH 8, DTT 0.5 mM) with 2 mg of poly-(dI-dC) for 10 min at 41C before the addition of labeled probe (0.25 ng). When indicated, an 80-fold excess of unlabeled competitor was added for 15 min. Samples were loaded onto an 8% native polyacrylamide gel in 0.25 Â TBE buffer. The oligonucleotides used were a TRE sequence contained in the MHC locus class II region: (AP-1) 5 0 -GGCTAGCTGACTCAGATGTCC or those derived from the human p14 ARF promoter: (p14-A) 5 0 -AGAATTGC TGAGTCAAAGGGTGT, (p14B) 5 0 -TACCCTTTGACTCA GCTATTCC and (p14C) 5 0 -TGCATAAGTGACCCACA GATAACTCA.
Retroviral infection
Cells were transduced as described previously (Bakiri et al., 2000) . Briefly, virus-containing culture supernatants were collected 24-72 h post-transfection, at 6 h intervals, and pooled. Cells were infected with filtered supernatants supplemented with 8 mg/ml polybrene (Sigma). After 24 h, the medium was replaced with fresh medium containing puromycin (Sigma) 2 mg/ml for MEFs or 4 mg/ml for NIH3T3 cells. At 2 to 6 days post-infection, puromycin-resistant clones were collected for analysis.
Western blot analysis and antibodies
Cells were lysed in RIPA buffer (50 mM Tris, pH 8, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) containing a cocktail of protease inhibitors (Roche). Western blot procedures were described previously (Ameyar et al., 1998) . Rabbit polyclonal antibodies to p19 ARF and a-actin were purchased from Abcam and Sigma, respectively. ERK, phospho-ERK and b-tubulin were purchased from Santa-Cruz. c-Jun antibody was as described previously .
'Real-time' PCR analysis RNA was isolated with RNeasy Mini kit (Qiagen). Firststrand cDNA (Invitrogen) was examined by real-time RT-PCR with specific primers and Sybro Green dye (Applied Biosystem) and the results were analysed using 7000 Sequence Detection System hardware and software (Applied Biosystem). We used the following primers: mouse 18S rRNA -5 0 -AACGAACGAGACTCGGCATG and 5 0 -CGGACATCTA AGGGCATCACA; p19 ARF -5 0 -AGGGTTTTCTTGGTGAA GTTCG and 5 0 -GCTCGCTGTCCTGGGTCTC.
Flow cytometry analysis
For flow cytometry analysis, cells were treated as described (Bakiri et al., 2000) . Analysis was carried out on an Epics XL Flow Cytometer (Coulter), and cell-cycle phases were estimated using the Multiplus Software (Phoenix Systems).
